Kirby Puckett dies; baseball great championed glaucoma awareness
April 15th 2006New York?When glaucoma suddenly stole vision from Minnesota Twins' Kirby Puckett's right eye and forced his retirement from Major League Baseball in 1996, it offered those in ophthalmology a remarkable opportunity to increase awareness about the disease.
Dual-laser blepharoplasty offers better eyelid results
April 15th 2006Atlanta?A 6-year study confirms the safety of dual-laser blepharoplasty for aesthetic rejuvenation of the upper and lower eyelids. Describing a series of 320 blepharoplasties, Harley Freiberger, MD, a dermatologic cosmetic surgeon in Los Angeles, reported that no permanent complications were observed, and that lesions healed rapidly and patients were quickly able to return to normal activity.
Squalamine safe, effective when administered with PDT
April 15th 2006Indianapolis?Squalamine lactate (Evizon, Genaera) seems to be safe and effective when administered with photodynamic therapy (PDT) using verteporfin (Visudyne, Novartis Ophthalmics/QLT Inc.) to patients with wet age-related macular degeneration (AMD), according to Thomas A. Ciulla, MD.
Smoking puts patients at risk for AMD
April 15th 2006Cambridge, England?Research published in the January issue of the British Journal of Ophthalmology found not only a strong association between pack years of cigarette smoking and age-related macular degeneration (AMD) but also an increased risk of AMD in nonsmokers exposed to passive smoking.
Modified version of Amsler grid improves scotoma detection
April 15th 2006Montr?al?A modified version of the Amsler grid, with a backlit screen and other changes, improves detection of scotomas and is easier for patients and clinicians to use, according to designer Elie Khouri, MD, a Montr?al ophthalmologist.
AREDS offers evidence of micronutrients' role in AMD
April 15th 2006Bethesda, MD?The Age-Related Eye Disease Study (AREDS) indicatedthat supplementation with micronutrients has a protective effect inpreventing the development of advanced stages of age-relatedmacular degeneration (AMD). Emily Y. Chew, MD, reviewed thefindings of the role of micronutrients for the treatment of AMD.
Ruboxistaurin tested in nonproliferative diabetic retinopathy
April 15th 2006Boston?Ruboxistaurin mesylate (Arxxant, Eli Lilly), an investigational drug that is an oral protein kinase C (PKC) beta inhibitor, reduced the occurrence of sustained moderate vision loss by 40% in patients with moderately severe to very severe nonproliferative diabetic retinopathy, reported Lloyd P. Aiello, MD, PhD.
Fluorescein angiography, OCT both useful technologies in retinal disease management
April 15th 2006Miami?Is it time to retire fluorescein angiography in light of the commercial availability of optical coherence tomography (OCT)? Certainly not, because they are complementary technologies that are integral to the management and treatment of retinal diseases, explained Carmen A. Puliafito, MD, MBA.
Ranibizumab trials provide hope for visual improvement
April 15th 2006Boston?The 12-month results of two randomized clinical trials of ranibizumab (Lucentis, Genentech) indicate that the drug shows encouraging signs of activity against vascular endothelial growth factor (VEGF) in age-related macular degeneration (AMD).
Pegaptanib may have expanded applications beyond AMD
April 15th 2006Cleveland?Anti-vascular endothelial growth factor (VEGF) therapy has been validated as the foundation treatment for age-related macular degeneration (AMD), stated Lawrence J. Singerman, MD, who provided an update on pegaptanib sodium (Macugen, OSI Pharmaceuticals/Eyetech Pharmaceuticals).
OCT valuable for evaluating treatment effects in CNV
April 15th 2006Miami?Optical coherence tomography (OCT) can be a valuable tool for evaluating the status of choroidal neovascularization (CNV) in patients with wet age-related macular degeneration (AMD), particularly when new drugs are being used to treat the disease, said Philip J. Rosenfeld, MD, PhD, associate professor of ophthalmology, Bascom Palmer Eye Institute, Miami.
Anecortave acetate found safe, effective in AMD
April 15th 2006New York?Anecortave acetate (Retaane 15 mg suspension, Alcon Laboratories) seems to be safe and effective for the treatment of exudative age-related macular degeneration (AMD) compared with photodynamic therapy (PDT) with verteporfin for injection (Visudyne, Novartis Ophthal-mics/QLT Inc.).
Intravitreal implant shows promise in DME, vein occlusion
April 15th 2006Durham, NC?The Retisert implant (Bausch & Lomb), a nonbiogradable device containing fluocinolone acetonide, is approved for the treatment of posterior uveitis and seems promising in the treatment of diabetic macular edema (DME) and vein occlusion in clinical trials, according to Glenn Jaffe, MD.
New treatment may usher new era for AMD patients
April 15th 2006Winter Haven, FL?A number of new pharmacologic options for exudative age-related macular degeneration (AMD), mostly designed to block different steps in the angiogenic cascade, are in various stages of development and testing, and some may one day be shown to improve outcomes, said Michael J. Tolentino, MD, director of clinical research, Center for Retina and Macular Disease, Winter Haven, FL.
Nonsurgical methods of vision corrrection should be option
April 15th 2006Minneapolis?Refractive surgeons should incorporate rather than dismiss corneal refractive therapy (orthokeratology) and contact lens fitting because those techniques can have a synergistic benefit rather than play a competitive role in a refractive surgery practice, according to David R. Hardten, MD.